Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
公司代碼QTRX
公司名稱Quanterix Corp
上市日期Dec 07, 2017
CEOToloue (Masoud)
員工數量471
證券類型Ordinary Share
年結日Dec 07
公司地址900 Middlesex Turnpike
城市BILLERICA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編01821
電話16173019400
網址https://www.quanterix.com/
公司代碼QTRX
上市日期Dec 07, 2017
CEOToloue (Masoud)